Metformin use and asthma outcomes among patients with concurrent asthma and diabetes

Chun Yi Li, Steven R. Erickson, Chung Hsuen Wu

研究成果: 雜誌貢獻文章

30 引文 (Scopus)

摘要

Background and objective: Metformin is a first-line treatment for patients with diabetes. Recent animal studies indicated that metformin can reduce airway inflammation. However, it remains unclear whether the use of metformin can help patients maintain asthma control. The purpose of this study was to evaluate the association between the use of metformin and asthma-related outcomes, which include asthma-related hospitalization, asthma-related emergency room visits and asthma exacerbation, among patients with concurrent asthma and diabetes. Methods: We conducted an 11-year (2001–2011) retrospective cohort study using the Taiwan National Health Insurance Research Database. Patients with concurrent asthma and diabetes were included. The date of the first observed prescription of metformin was defined as the index date. For each metformin user, two matched metformin non-users of the same age and gender were randomly selected. Patients were followed for 3 years to measure the occurrence of asthma-related outcomes. Multivariable logistic regression models were used to assess the association between metformin use and asthma-related outcomes. Results: Of 1332 patients with concurrent asthma and diabetes, 444 (33.3%) were metformin users. Compared with non-users, metformin users had a lower risk of asthma-related hospitalization (OR = 0.21, 95% CI: 0.07–0.63) and asthma exacerbation (OR = 0.39, 95% CI: 0.19–0.79). Conclusion: The risk of asthma-related outcomes was lower for metformin users than non-users. Health-care providers should consider metformin as a treatment strategy for patients with concurrent asthma and diabetes.
原文英語
頁(從 - 到)1210-1218
頁數9
期刊Respirology
21
發行號7
DOIs
出版狀態已發佈 - 十月 1 2016

指紋

Metformin
Asthma
Hospitalization
Logistic Models
National Health Programs
Taiwan
Health Personnel
Prescriptions
Hospital Emergency Service
Cohort Studies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

引用此文

Metformin use and asthma outcomes among patients with concurrent asthma and diabetes. / Li, Chun Yi; Erickson, Steven R.; Wu, Chung Hsuen.

於: Respirology, 卷 21, 編號 7, 01.10.2016, p. 1210-1218.

研究成果: 雜誌貢獻文章

Li, Chun Yi ; Erickson, Steven R. ; Wu, Chung Hsuen. / Metformin use and asthma outcomes among patients with concurrent asthma and diabetes. 於: Respirology. 2016 ; 卷 21, 編號 7. 頁 1210-1218.
@article{75c2f45cedf546b78f7336268179136c,
title = "Metformin use and asthma outcomes among patients with concurrent asthma and diabetes",
abstract = "Background and objective: Metformin is a first-line treatment for patients with diabetes. Recent animal studies indicated that metformin can reduce airway inflammation. However, it remains unclear whether the use of metformin can help patients maintain asthma control. The purpose of this study was to evaluate the association between the use of metformin and asthma-related outcomes, which include asthma-related hospitalization, asthma-related emergency room visits and asthma exacerbation, among patients with concurrent asthma and diabetes. Methods: We conducted an 11-year (2001–2011) retrospective cohort study using the Taiwan National Health Insurance Research Database. Patients with concurrent asthma and diabetes were included. The date of the first observed prescription of metformin was defined as the index date. For each metformin user, two matched metformin non-users of the same age and gender were randomly selected. Patients were followed for 3 years to measure the occurrence of asthma-related outcomes. Multivariable logistic regression models were used to assess the association between metformin use and asthma-related outcomes. Results: Of 1332 patients with concurrent asthma and diabetes, 444 (33.3{\%}) were metformin users. Compared with non-users, metformin users had a lower risk of asthma-related hospitalization (OR = 0.21, 95{\%} CI: 0.07–0.63) and asthma exacerbation (OR = 0.39, 95{\%} CI: 0.19–0.79). Conclusion: The risk of asthma-related outcomes was lower for metformin users than non-users. Health-care providers should consider metformin as a treatment strategy for patients with concurrent asthma and diabetes.",
keywords = "asthma, claims data, diabetes, metformin, The National Health Insurance Research Database",
author = "Li, {Chun Yi} and Erickson, {Steven R.} and Wu, {Chung Hsuen}",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/resp.12818",
language = "English",
volume = "21",
pages = "1210--1218",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Metformin use and asthma outcomes among patients with concurrent asthma and diabetes

AU - Li, Chun Yi

AU - Erickson, Steven R.

AU - Wu, Chung Hsuen

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background and objective: Metformin is a first-line treatment for patients with diabetes. Recent animal studies indicated that metformin can reduce airway inflammation. However, it remains unclear whether the use of metformin can help patients maintain asthma control. The purpose of this study was to evaluate the association between the use of metformin and asthma-related outcomes, which include asthma-related hospitalization, asthma-related emergency room visits and asthma exacerbation, among patients with concurrent asthma and diabetes. Methods: We conducted an 11-year (2001–2011) retrospective cohort study using the Taiwan National Health Insurance Research Database. Patients with concurrent asthma and diabetes were included. The date of the first observed prescription of metformin was defined as the index date. For each metformin user, two matched metformin non-users of the same age and gender were randomly selected. Patients were followed for 3 years to measure the occurrence of asthma-related outcomes. Multivariable logistic regression models were used to assess the association between metformin use and asthma-related outcomes. Results: Of 1332 patients with concurrent asthma and diabetes, 444 (33.3%) were metformin users. Compared with non-users, metformin users had a lower risk of asthma-related hospitalization (OR = 0.21, 95% CI: 0.07–0.63) and asthma exacerbation (OR = 0.39, 95% CI: 0.19–0.79). Conclusion: The risk of asthma-related outcomes was lower for metformin users than non-users. Health-care providers should consider metformin as a treatment strategy for patients with concurrent asthma and diabetes.

AB - Background and objective: Metformin is a first-line treatment for patients with diabetes. Recent animal studies indicated that metformin can reduce airway inflammation. However, it remains unclear whether the use of metformin can help patients maintain asthma control. The purpose of this study was to evaluate the association between the use of metformin and asthma-related outcomes, which include asthma-related hospitalization, asthma-related emergency room visits and asthma exacerbation, among patients with concurrent asthma and diabetes. Methods: We conducted an 11-year (2001–2011) retrospective cohort study using the Taiwan National Health Insurance Research Database. Patients with concurrent asthma and diabetes were included. The date of the first observed prescription of metformin was defined as the index date. For each metformin user, two matched metformin non-users of the same age and gender were randomly selected. Patients were followed for 3 years to measure the occurrence of asthma-related outcomes. Multivariable logistic regression models were used to assess the association between metformin use and asthma-related outcomes. Results: Of 1332 patients with concurrent asthma and diabetes, 444 (33.3%) were metformin users. Compared with non-users, metformin users had a lower risk of asthma-related hospitalization (OR = 0.21, 95% CI: 0.07–0.63) and asthma exacerbation (OR = 0.39, 95% CI: 0.19–0.79). Conclusion: The risk of asthma-related outcomes was lower for metformin users than non-users. Health-care providers should consider metformin as a treatment strategy for patients with concurrent asthma and diabetes.

KW - asthma

KW - claims data

KW - diabetes

KW - metformin

KW - The National Health Insurance Research Database

UR - http://www.scopus.com/inward/record.url?scp=84987623306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987623306&partnerID=8YFLogxK

U2 - 10.1111/resp.12818

DO - 10.1111/resp.12818

M3 - Article

C2 - 27245632

AN - SCOPUS:84987623306

VL - 21

SP - 1210

EP - 1218

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 7

ER -